A Guide to Bone Marrow Transplantation

  • Hans Joachim Deeg
  • Hans-Georg Klingemann
  • Gordon L. Phillips

Table of contents

  1. Front Matter
    Pages I-VIII
  2. Introduction

    1. H. J. Deeg
      Pages 1-3
  3. Pre-Transplant Considerations

    1. Front Matter
      Pages 5-5
    2. G. L. Phillips
      Pages 26-42
    3. H. J. Deeg
      Pages 43-44
  4. Transplant Procedure

    1. Front Matter
      Pages 45-45
    2. H. J. Deeg
      Pages 47-52
    3. G. L. Phillips
      Pages 53-70
    4. H.-G. Klingemann
      Pages 71-77
  5. Acute Transplant Related Problems

    1. Front Matter
      Pages 79-79
    2. G. L. Phillips
      Pages 81-85
    3. H. J. Deeg
      Pages 86-98
    4. H. J. Deeg
      Pages 99-106
    5. G. L. Phillips
      Pages 107-113
    6. H. J. Deeg
      Pages 114-122
    7. H.-G. Klingemann
      Pages 123-134
    8. H.-G. Klingemann
      Pages 135-139
    9. H.-G. Klingemann
      Pages 140-148
  6. Delayed Transplant Related Problems

    1. Front Matter
      Pages 149-149
    2. H.-G. Klingemann
      Pages 156-169
    3. H.-G. Klingemann
      Pages 170-173
    4. H. J. Deeg
      Pages 178-179
    5. H. J. Deeg
      Pages 180-182
    6. H. J. Deeg
      Pages 183-184
  7. Future Developments

    1. H. J. Deeg
      Pages 185-189
  8. Back Matter
    Pages 190-192

About this book


In the late 1940s investigators observed that mice given supralethai doses of total body irradiation were protected by infusion of viable spleen or marrow cells following irradiation, and that this was accomplished by hemopoietic reconsti­ tution with donor cells as proven using genetic markers. If a similar approach could be applied to humans, it should be possible to treat leukemia patients with any dose of chemoradiotherapy as far as nonmarrow toxicity permitted, and then rescue them by marrow transplantation. Early clinical attempts were gen­ erally unsuccessful, mostly due to a lack of knowledge of histocompatibility antigens and appropriate supportive care. These areas developed rather quickly during the 1960s, and for almost two decades now clinical marrow transplan­ tation has been carried out with increasing success. After initially using only bone marrow from HLA indentical siblings, the field has expanded rapidly to incorporate HLA nonidentical related donors, and recently even marrow from unrelated volunteer donors. Furthermore, since for numerous patients who oth­ erwise could benefit from transplantation a donor cannot be identified, there has been a growing interest in using the patient's own (autologous) bone marrow. Our understanding of the principles of transplantation and our knowledge of the potential risks and benefits have quickly grown. At times it is difficult, however, to decide what is the best option for a given patient.


Bone Marrow Transplantation Knochenmarkstransplantation Krebstherapie Leukämie bone marrow cancer cancer therapy central nervous system growth hematopoietic stem cell transplantation leukemia nervous system therapy transplantation

Authors and affiliations

  • Hans Joachim Deeg
    • 1
  • Hans-Georg Klingemann
    • 2
  • Gordon L. Phillips
    • 2
  1. 1.Vincent T. Lombardi Cancer Research CenterGeorgetown University Medical CenterN.W.USA
  2. 2.Leukemia/Bone Marrow Transplant Program of B.C.University of British ColumbiaVancouverCanada

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1988
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-97079-5
  • Online ISBN 978-3-642-97077-1
  • Buy this book on publisher's site